Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients
Medicare officials said they would cover Biogen Inc.’s BIIB 2.64% controversial Alzheimer’s disease drug Aduhelm on the condition that patients...
Medicare officials said they would cover Biogen Inc.’s BIIB 2.64% controversial Alzheimer’s disease drug Aduhelm on the condition that patients...
The Biden administration took steps Wednesday to crack down on rising Covid-19 cases, including a call for a third shot...
A collection agent for Medicare service providers is suing one of the dozens of trusts established by bankrupt asbestos manufacturers...